NAVIDEA BIOPHARMACEUTICALS INC Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will participate in the BTIG Emerging Technologies in Healthcare Diagnostics investor conference taking place September 29th and 30th in New York.
Interim Chief Executive Officer Michael Goldberg, M.D., will participate in the following panels on Tuesday, September 30th:
- Cell Specific Imaging/Biopsy Assistance
- Innovations in Diagnosing Alzheimer’s
- Laboratory vs. Hospital Launch
The conference is organized as a series of panel discussions designed to inform investors on trends, technologies, and organizations shaping the healthcare diagnostics industry. As a result of the format, a webcast will not be available.
About Navidea Biopharmaceuticals, Inc.
Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing
multiple precision diagnostic products and platforms including
Manocept™, NAV4694, NAV5001, and NAV1800 (RIGScan™), to help identify
the sites and pathways of undetected disease and enable better
diagnostic accuracy, clinical decision-making and, ultimately, patient
care. Lymphoseek® (technetium Tc 99m tilmanocept) Injection,
Navidea’s first commercial product from the Manocept platform, was
approved by the FDA in March 2013. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
radiopharmaceutical agents and advancing the Company’s pipeline through
selective acquisitions, global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
